{"id":2316,"date":"2024-12-22T21:48:35","date_gmt":"2024-12-22T21:48:35","guid":{"rendered":"https:\/\/www.inab.certh.gr\/project\/smzl-ibru-ezh2\/"},"modified":"2024-12-22T21:48:35","modified_gmt":"2024-12-22T21:48:35","slug":"smzl-ibru-ezh2","status":"publish","type":"project","link":"https:\/\/www.inab.certh.gr\/el\/project\/smzl-ibru-ezh2\/","title":{"rendered":"SMZL-Ibru-EZH2"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The Research Program aims at: 1)<\/span> <span style=\"font-weight: 400;\">Detailed characterization of immune signaling capacity of SMZL B cells, in order to obtain deeper insight into the precise role of signaling inhibitors in SMZL management, 2) screening and functional characterization of EZH2, a marker of clinical aggressiveness and druggable target in lymphoma (Wagener, Macher-Goeppinger et al. 2010, Beguelin, Popovic et al. 2013, Behrens, Solis et al. 2013), in well a characterized cohort of SMZL case, and 3) investigation of the effects and potential synergism of combined EZH2 and signaling inhibition in SMZL cells ex vivo.<\/span><\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"class_list":["post-2316","project","type-project","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.inab.certh.gr\/el\/wp-json\/wp\/v2\/project\/2316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inab.certh.gr\/el\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.inab.certh.gr\/el\/wp-json\/wp\/v2\/types\/project"}],"wp:attachment":[{"href":"https:\/\/www.inab.certh.gr\/el\/wp-json\/wp\/v2\/media?parent=2316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}